primobolan for women
With increasing doses of the combination piperacillin, respectively, there is a disproportionate increase (approximately 28%) concentrations of piperacillin and tazobactam.
Plasma protein binding of both piperacillin and tazobactam is approximately 30%, with this presence of tazobactam no effect on this parameter piperacillin, and the presence of piperacillin primobolan for women is widely distributed in tissues and body fluids including, in the intestinal mucosa, gall bladder, lung, bile, female genital organs (uterus, ovary and fallopian tubes) and bones. Mean tissue concentrations ranging from 50 to 100% concentration in plasma.
Piperacillin is metabolized to less active dezetilmetabolita; tazobactam -up an inactive metabolite. Piperacillin and tazobactam excreted by the kidneys by glomerular filtration and tubular secretion.Piperacillin is excreted rapidly as unchanged, 68% of the dose found in the urine. Tazobactam and its metabolite are rapidly eliminated by renal excretion, 80% of the dose found in an unmodified form, and the remaining amount of a metabolite. Piperacillin, tazobactam, and dezetilpiperatsillin also excreted in the bile and intestines are derived.
The of piperacillin and tazobactam plasma is 0.7-1.2 hours. With a decrease in creatinine clearance half-life of piperacillin and tazobactam lengthened.
As the decline in creatinine clearance half-lives of piperacillin and tazobactam are increased. By reducing creatinine clearance less than 20 mL / min half-lives of piperacillin and tazobactam as compared to patients with normal renal function increases of 2 and 4 times, respectively.
During hemodialysis derived from 30 to 50% of piperacillin and 5% of the dose of tazobactam in the form of a metabolite. In carrying out the peritoneal dialysis is output, respectively, about 6 and 21% of tazobactam and piperacillin, and tazobactam 18% output to form a metabolite.
Abnormal liver function
Although patients with hepatic impairment half-lives of piperacillin and tazobactam increases function, dose adjustment is required.
Infectious-inflammatory primobolan for women diseases caused by susceptible to piperacillin / tazobactam microorganisms.
Adults and children over 12 years:
- Lower respiratory tract infections;
- Urinary tract infections (complicated and uncomplicated);
- Intra-abdominal infections;
- Infections of the skin and soft tissues;
- Gynecological infections (including endometritis and adnexitis postpartum);
- Bacterial infection in patients with neutropenia (in combination with aminoglycosides);
- Bone and joint infections;
- Mixed infections (caused by gram-positive / gram-negative aerobic and anaerobic microorganisms).Children aged 2 to 12 years:
- Intra-abdominal infections;
- Infections of neutropenia (in combination with aminoglycosides).
Increased sensitivity to beta-lactam antibiotics (including penicillin, cephalosporins), or other ingredients to inhibitors of beta-lactamase.Children under 2 years old.
Severe bleeding (including history), cystic primobolan for women fibrosis (increased risk of hyperthermia and skin rash), pseudomembranous colitis, children’s age, renal insufficiency (creatinine clearance less than 20 ml / min), patients on hemodialysis, at the joint use of high doses of anticoagulants, with hypokalemia.